GSK•GSK has agreed to acquire oncology specialist Nuvalent for $10.6 billion, bolstering its pipeline and ending a prolonged mid-cap biotech M&A drought. Shares jumped 3.3% to $52.86, marking a 31.8% year-over-year gain, even as GF Value warns the stock may now be overvalued.
GSK has struck a $10.6 billion deal to acquire Nuvalent, a mid-cap oncology specialist, adding targeted therapies and preclinical assets to its cancer portfolio. The transaction ends a stretch of low M&A activity in the biotech sector and aims to strengthen GSK’s position in precision oncology.
Following the announcement, GSK shares rose 3.3% to $52.86, extending a 31.8% gain over the past year. Despite positive investor response, GF Value’s analysis suggests the stock may now be trading at a premium to its intrinsic value.
Gurufocus
